We also examined the effects of combined genotypes of MTHFR A1298C and C677T, MTHFR A1298C and MTR A2756G, and MTHFR C677T and MTR A2756G, none of which was statistically significantly associated with the risk of breast cancer compared to their wild genotypes.
TWIST system selected 6 variables (BNMN frequency, MTHFR 677TT, RFC1 80AA, TYMS 1494 6bp +/+, TYMS 28bp 3R/3R and MTR 2756AA genotypes) that were subsequently used to discriminate between MDS and control mothers with 90% accuracy.
Genotyping was completed for MTHFR A1298C and C677T, and MTR A2756G polymorphisms.
Averages of each patient's T1, T2, T2*, and MTR lesion z-scores were also performed in the whole MS group.
In Figure 3, some representative maps of T1W, T2W, MTR, MD and FA are shown for each group of animals.
456 NVAF patients and 912 matched controls were genotyped by an electronic microchip technology for C677T and A1298C MTHFR, A2756G MTR, and -786C/T eNOS gene polymorphisms.
Table 3 shows C677T MTHFR, A1298C MTHFR, A2756G MTR and −786 C/T eNOS polymorphism genotype distributions and tHcy levels according to genotypes in patients and controls.
The C677T MTHFR, A1298C MTHFR, A2756G MTR and −786 C/T eNOS genotype distributions were in Hardy-Weinberg equilibrium in patients and controls.
Adjusted Hcy mean values for C677T MTHFR, A1298C MTHFR, A2756G MTR and −786 C/T eNOS genotypes were estimated from linear models adjusted for sex, age and creatinine.
